接受中等纯度因子VIII浓缩物或因子IX复合物治疗的既往未治疗患者中抑制剂发生率为零。 - Suppr | 超能文献

Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.

作者信息

Schimpf K, Schwarz P, Kunschak M

出版信息

Thromb Haemost. 1995 Mar;73(3):553-5.

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.接受中等纯度因子VIII浓缩物或因子IX复合物治疗的既往未治疗患者中抑制剂发生率为零。

Thromb Haemost. 1995 Mar;73(3):553-5.

2

Inhibitor antibodies to factor VIII and factor IX: management.针对凝血因子VIII和凝血因子IX的抑制性抗体：管理

Semin Thromb Hemost. 2000;26(2):179-88. doi: 10.1055/s-2000-9821.

3

[Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors].[关于血友病抑制物患者治疗与生活质量的前瞻性配对对照研究]

Rinsho Ketsueki. 1998 Jun;39(6):416-21.

4

The management of hemophilia patients with inhibitors.血友病抑制物患者的管理

Transfus Med Rev. 1992 Oct;6(4):285-93. doi: 10.1016/s0887-7963(92)70185-0.

5

Transfusion support for haemophiliacs.血友病患者的输血支持。

Clin Haematol. 1984 Feb;13(1):99-117.

6

[Treatment of hemophiliacs with inhibitors].[血友病抑制剂患者的治疗]

Rinsho Ketsueki. 1985 Jul;26(7):1059-68.

7

Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.先天性血友病中因子 VIII 和 IX 抑制剂的诊断与治疗：（第4版）。英国血友病中心医生组织。

Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15.

8

Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.两剂重组活化凝血因子VII（诺其）用于有抑制物的血友病患者手术的前瞻性随机试验

Thromb Haemost. 1998 Nov;80(5):773-8.

9

[Risk of the appearance of inhibitors linked to the administration of factors VIII and IX. Review of the literature].[与 VIII 因子和 IX 因子给药相关的抑制剂出现风险。文献综述]

Transfus Clin Biol. 1994;1(6):427-35. doi: 10.1016/s1246-7820(06)80027-3.

10

Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.伴有凝血因子VIII和IX抑制剂的患者的治疗，特别关注重组凝血因子VIIa的使用。

Thromb Haemost. 1999 Aug;82(2):531-9.

引用本文的文献

1

Product type and other environmental risk factors for inhibitor development in severe hemophilia A.重度A型血友病中抑制剂产生的产品类型及其他环境风险因素

Res Pract Thromb Haemost. 2018 Apr 10;2(2):220-227. doi: 10.1002/rth2.12094. eCollection 2018 Apr.

2

Factor VIII safety: plasma-derived versus recombinant products.凝血因子VIII的安全性：血浆源性产品与重组产品

Blood Transfus. 2011 Oct;9(4):366-70. doi: 10.2450/2011.0092-10. Epub 2011 Apr 12.